Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

46.86 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
76 77 Next >
Regulatory Applications Accepted in the U.S. and Japan for Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma (FL) and Relapsed or Refractory Mantle Cell Lymphoma (MCL)
From Bristol Myers Squibb
Via Business Wire
Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate
Via Get News
Bristol Myers' Lead Cancer Drug Opdivo Formulated As Under Skin Injection At Par With Intravenous Infusion In Kidney Cancer Patients
Results from Bristol Myers Squibb's Phase 3 CheckMate -67T trial on subcutaneous Opdivo (nivolumab) for advanced clear cell renal cell carcinoma. Noninferiority compared to IV Opdivo. 
Via Benzinga
Is Bristol Myers Squibb Stock a Buy Now?
This healthcare stock has seen healthier days. 
Via The Motley Fool
Uncovering Dividend Opportunities with NYSE:BMY.
Analyzing BRISTOL-MYERS SQUIBB CO (NYSE:BMY)'s Dividend Potential. 
Via Chartmill
Behind the Scenes of Bristol-Myers Squibb's Latest Options Trends
Via Benzinga
Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate
--News Direct-- 
Via News Direct
Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate
New York, Jan. 29, 2024 - (Plato Data) -- Corbus Pharmaceuticals (NASDAQ:CRBP) jumped on Friday after announcing positive data from a small group of cancer patients who received its antibody-drug... 
Via TheNewswire.com
Subcutaneous Nivolumab (nivolumab and hyaluronidase) Shows Noninferiority Compared to Intravenous Opdivo (nivolumab) in Advanced or Metastatic Clear Cell Renal Cell Carcinoma in CheckMate -67T Trial
From Bristol Myers Squibb
Via Business Wire
Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism?
An analyst sees the Satya Nadella-led company's earnings to be the key barometer for AI spending. 
Via Benzinga
Topics Artificial Intelligence
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Karuna Therapeutics, Inc. (Nasdaq – KRTX), Carrols Restaurant Group, Inc. (Nasdaq - TAST), Ansys, Inc. (Nasdaq - ANSS), HomeStreet, Inc. (Nasdaq - HMST)
From Brodsky & Smith LLC
Via GlobeNewswire
3 Healthcare Stocks at 52-Week Lows: Buy or Bye?
Investors should consider picking up these healthcare stocks at 52-week lows to benefit from their potential rebound. 
Via InvestorPlace
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
From Bristol Myers Squibb
Via Business Wire
Gilead's Tecartus Dropped From FDA List Of CAR-T Therapy With Updated Label Warning Of "Risks Of Secondary Cancer'
FDA issues classwide black box warning for CAR-T therapies due to T-cell cancer risk. Drops Gilead's cell therapy from the list. 
Via Benzinga
7 Beaten-Down Value Stocks Poised for an Epic Turnaround
Battered value stocks could be priced for an epic rebound in 2024 and beyond. These seven can quickly escape Wall Street's penalty box. 
Via InvestorPlace
Bristol Myers, Exelixis Reveal 4-Year Follow-Up Results From Cancer Treatment Study
Bristol Myers Squibb & Exelixis Inc revealed four-year follow-up results from CheckMate -9ER trial. 
Via Benzinga
Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics, Strengthening and Diversifying Oncology Portfolio
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb's Combo Therapy Shows Sustained Benefits Over Pfizer's Cancer Drug In Kidney Cancer Patients After 8 Years Of Followup
Bristol Myer's Opdivo/Yervoy's long-term survival benefits in CheckMate-214 trial for advanced renal cell carcinoma. Significant reductions in risk of death, improved OS, PFS, and ORR after eight... 
Via Benzinga
Focus On Bristol Myers, Gilead Sciences, Johnson & Johnson, Novartis: FDA To Issue Classwide Black Box Warning on CAR-T Therapies For Blood Cancer Treatment
In a significant development, the FDA is set to impose a classwide black box warning following its investigation into secondary T-cell cancers arising from the use of existing CAR-T therapies.  
Via Benzinga
Eight-Year Data for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Continue to Demonstrate Longest Survival Benefit vs. Sunitinib Reported in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
From Bristol Myers Squibb
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Karuna Therapeutics, Inc. (Nasdaq – KRTX), Carrols Restaurant Group, Inc. (Nasdaq - TAST), Ansys, Inc. (Nasdaq - ANSS), HomeStreet, Inc. (Nasdaq - HMST)
From Brodsky & Smith LLC
Via GlobeNewswire
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
From Bristol Myers Squibb
Via Business Wire
Bristol Myers' Lead Cancer Immunotherapy Shows Progression Free Survival Versus Chemo In Certain Type Of Colorectal Cancer
Bristol Myers' Opdivo + Yervoy combo shows 79% reduced risk in MSI-H/dMMR metastatic colorectal cancer. 
Via Benzinga
Opdivo (nivolumab) Plus Yervoy (ipilimumab) Reduced the Risk of Disease Progression or Death by 79% Versus Chemotherapy in Patients with Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer in CheckMate -8HW Trial
From Bristol Myers Squibb
Via Business Wire
Ikena Oncology Refocuses on Key Programs: Analysts Maintain Outperform Ratings Amid Strategic Organizational Changes
Ikena Oncology optimizes resources for targeted oncology programs IK-930 & IK-595. Clinical updates expected H2 2024. Workforce reduced by 35%. Financially secure with $175M cash. Strategic focus on... 
Via Benzinga
Inflation-Busting Price Hikes For Ozempic, Mounjaro And Others: Are Drugmakers Profiteering?
Pharmaceuticals prices are already up in 2024: Can inflation-beating hikes be justified? 
Via Benzinga
Bristol Myers Squibb Data at ASCO GU 2024 Showcase Transformative Research in the Treatment of Genitourinary Cancers
From Bristol Myers Squibb
Via Business Wire
Financial Relief For Medicare Patients: Part D Overhaul Caps Out-of-Pocket Drug Cost Limits
In 2024, the Inflation Reduction Act limits out-of-pocket drug costs to $3,300 annually, with further reductions to $2,000 in 2025. 
Via Benzinga
Topics Economy
Cytokinetics' Heart Drug Is A Multi-Billion Dollar Opportunity By 2032 Despite Novartis Setback: Analyst
Novartis halts pursuit of Cytokinetics acquisition, impacting promising heart drug. Analysts estimate $3.6 billion sales for Cytokinetics' cardiomyopathy drug by 2032. Still lead drug aficamten viewed... 
Via Benzinga
Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space
The companies are working on blocking TL1A, a protein tied to inflammatory bowel disease. 
Via Investor's Business Daily
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
76 77 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback